Corvus Pill Shows Promise in Eczema Trial
- The Food and Drug Administration (FDA) granted conventional approval to Biogen's lecanemab (Leqembi) on July 6, 2023, marking a meaningful turning point in the treatment of early Alzheimer's...
- Lecanemab is a human monoclonal antibody designed to target and clear amyloid beta plaques, a hallmark of Alzheimer's disease, from the brain.
- The Clarity AD trial, involving 1,795 participants, demonstrated a 27% slowing of cognitive decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over 18 months.
“`html
Biogen’s Lecanemab and the Future of Alzheimer’s Treatment
Table of Contents
The Food and Drug Administration (FDA) granted conventional approval to Biogen’s lecanemab (Leqembi) on July 6, 2023, marking a meaningful turning point in the treatment of early Alzheimer’s disease. This approval,based on data from the Phase 3 clarity AD clinical trial,represents the first time an anti-amyloid antibody has received full FDA approval for slowing the progression of the disease,rather than simply addressing symptoms.
What is Lecanemab (Leqembi)?
Lecanemab is a human monoclonal antibody designed to target and clear amyloid beta plaques, a hallmark of Alzheimer’s disease, from the brain. It’s administered intravenously every two weeks and is indicated for patients with early-stage Alzheimer’s disease, specifically those with mild cognitive impairment or mild dementia and confirmed presence of amyloid beta pathology.
The Clarity AD trial, involving 1,795 participants, demonstrated a 27% slowing of cognitive decline as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over 18 months. Though,the treatment is not without risks,including amyloid-related imaging abnormalities (ARIA),which can cause brain swelling or bleeding. FDA Q&A on Lecanemab provides detailed details on ARIA and monitoring protocols.
Example: In the Clarity AD trial, 12.5% of participants receiving lecanemab experienced ARIA-E (edema or swelling) compared to 1.8% in the placebo group. New England Journal of Medicine – Lecanemab in Early Alzheimer’s Disease
FDA Approval Process and Controversy
The FDA’s approval pathway for lecanemab was not without scrutiny. Initially, the agency granted accelerated approval in January 2023 based on promising biomarker data, but required Biogen to conduct a confirmatory Phase 3 trial. The full approval in July 2023 followed the positive results of the Clarity AD trial.
The approval process drew criticism due to concerns about the drug’s efficacy and safety, as well as questions about the FDA’s review process.The agency faced pressure from patient advocacy groups and medical experts to ensure rigorous evaluation. CMS Proposes Coverage of Lecanemab details the Medicare coverage decision, which initially limited access to patients enrolled in clinical trials.
official statement: “The FDA’s approval of Leqembi is a significant step forward in the fight against Alzheimer’s disease,” stated Dr. Billy Dunn, Director of the Office of Neuroscience at the FDA, in a July 6, 2023 FDA Press Release.
Cost and Access to Lecanemab
Lecanemab carries a significant price tag of $26,500 per year, based on the average weight of a patient requiring the full dosage. this cost raises concerns about accessibility, especially for Medicare beneficiaries.
The Centers for Medicare & Medicaid Services (CMS) initially proposed limited coverage for lecanemab, requiring participation in clinical trials or registries. Though, in February 2024, CMS announced broader coverage for lecanemab for Medicare beneficiaries who meet specific criteria, including diagnosis by a qualified physician and participation in a patient registry. CMS Finalizes Coverage of Lecanemab
Financial Data: Biogen reported $219 million in Leqembi revenue for the fourth quarter of 2023. Biogen Q4 2023 Earnings Report